

For Immediate Release**MedX Health Corp Reports First Quarter 2009 Financial Results**

36% Gain in Q1 2009 Compared to Q4 2008

Mississauga, ON – May 27, 2009 – MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced its results for the quarter ended March 31, 2009.

Revenue for the quarter ended March 31, 2009 was \$351,575, an 18.9 % increase over the same period in 2008 where revenue was \$295,582. This revenue also represents a 35.7% increase over revenues in the previous quarter. MedX incurred a loss from continuing operations for the quarter of \$408,458 or \$0.02 per share compared to a loss of \$688,604 or \$0.04 per share for the same period in the prior year.

“MedX continues to post strong revenue increases versus recent prior periods in 2008,” said Steven Guillen, chief executive officer and president of MedX Health. “This quarter’s strong growth is a direct result of Medx’s entry into the international marketplace as it made its first major shipments into the European market after obtaining the CE mark approval for all its products. Our two new strategic partnerships with Technology4Medicine and Richmar/Naimco, continue to show excellent potential for future growth. We are pleased with the revenue growth over the last nine months, especially in light of the difficult market conditions. We expect to continue this trend of revenue growth for the remainder of 2009.”

Recent Company Highlights:

- Received CE mark for all products, which allows MedX to begin selling in 27 countries associated with the European Community (*MedX Health Receives CE Mark for Laser and Light Products, March 4, 2009*).
- Launched IRB (Investigational Review Board) approved program for treating addictions; smoking, alcohol, and drug abuse. This incorporates the MedX acupuncture laser with expert training with the goal of expanding the scope of an individual practice to a full franchise opportunity (*MedX Health Announces Initiation of Laser Acupuncture Study for Controlling Addiction, January 22, 2009*).
- Achieved ISO re-certification, demonstrating to outside regulatory bodies that the highest quality standards are in place (*MedX Health Receives CE Mark for Laser and Light Products, March 4, 2009*).
- Announced a newly allowed wound healing patent covering a laser and light therapy apparatus and method for bone healing, bone growth stimulation, and bone cartilage regeneration (*MedX Health Announces Patent Allowance for Use of Laser and Light Probe for Bone Healing, February 23, 2009*).

Canadian \$	Q1 2009	Q1 2008
Revenue	351,575	295,582
Gross Margin %	54.2%	69.0%
Loss from continued operations	(403,364)	(687,144)
Loss from discontinued operations	(5,094)	(1,460)
Loss for the period	(408,458)	(688,604)
Weighted Average no. of shares outstanding-basic	27,128,527	15,043,937
Loss per Common Share-basic and diluted	(\$0.02)	(\$0.04)

About MedX Health Corp.

MedX is a leading North American developer and manufacturer of low level laser and light medical devices for the drug free and non-invasive treatment of tissue damage and pain in numerous medical settings including dental, rehabilitation and wound care. MedX is the world's only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for and bringing the non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments. MedX's strategy is to build upon its success in bringing relief of symptoms in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as well as developing and commercializing advanced products in the dental and wound-care markets that will position the company to increase revenue. In addition, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its "Photobandage™", a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

Brand products are US FDA approved, Health Canada cleared, and CE Marked and are produced in an ISO 9001 and 13485 certified manufacturing and testing facility. For a complete profile of MedX Health Corp. and its products visit www.medXhealth.com

Contacts:

Investors:

Steve Guillen
 President and Chief Executive Officer
 MedX Health Corp.
 Phone: (905) 826-0766
info@medxhealth.com

Media:

Terri Clevenger
Continuum Health Communications
Phone (203) 227-0209
Email: tclevenger@continuumhealthcom.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.